Ritu Pandey
Overview
Explore the profile of Ritu Pandey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Subramani B, Conway P, Al-Khinji A, Zhang K, Pandey R, Mahadevan D
Cancers (Basel)
. 2025 Jan;
16(24.
PMID: 39766156
: Aurora (AK) A/B are oncogenic mitotic kinases that when over-expressed are poor prognostic markers in mantle cell lymphoma (MCL). : Alisertib, an AK-A inhibitor, has anti-tumor activity in relapsed/refractory...
2.
Tiwari S, Pandey R, Kumar V, Das S, Gupta V, Nema R, et al.
Noncoding RNA Res
. 2024 Aug;
9(4):1333-1341.
PMID: 39131689
The disease burden of Oral Squamous Cell Carcinoma (OSCC) is rising day-by-day and is expected to rise 62 % through 2035. The chewing of tobacco, areca nut, and betel leaf,...
3.
Morrison C, Weterings E, Gravbrot N, Hammer M, Weinand M, Sanan A, et al.
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612480
The aim of this study was to investigate gene expression alterations associated with overall survival (OS) in glioblastoma (GBM). Using the Nanostring nCounter platform, we identified four genes (, and...
4.
Lou E, Xiu J, Baca Y, Saeed A, Prakash A, Gholami S, et al.
Mol Ther Oncol
. 2024 Apr;
32(1):200786.
PMID: 38596288
Oncogenic drivers such as extensively modulate the tumor inflammatory microenvironment (TIME) of colorectal cancer (CRC). The influence of on modulating immune cell composition remains unclear. The objective of this study...
5.
Nema R, Pandey R, Kumar A
Asian Pac J Cancer Prev
. 2024 Mar;
25(3):725-733.
PMID: 38546054
Objective: Availability of multimodal treatment strategies, including targeted therapies and immunotherapies, have improved the survival of non-small cell lung carcinoma (NSCLC). However, some patients still progress or respond poorly due...
6.
Tiwari S, Pandey R, Kumar V, Das S, Gupta V, Vishwakarma S, et al.
Cancer Biomark
. 2023 Aug;
38(2):203-214.
PMID: 37545224
Background: miRNAs play a crucial role in the genesis of cancer, either as tumor suppressor genes or as oncogenes. Single Nucleotide Polymorphisms (SNPs) in the seed region of microRNAs (miRNAs)...
7.
Pandey R, Nema R, Vishwakarma S, Singh A, Mohan S, Patel P, et al.
Asian Pac J Cancer Prev
. 2023 Jul;
24(7):2353-2360.
PMID: 37505766
Oral squamous cell carcinoma (OSCC) is the most common type of cancer among men in the Indian subcontinent. Cytokines regulate inflammation and angiogenesis in a variety of cancers. Genetic variability...
8.
Song H, Sontz R, Vance M, Morris J, Sheriff S, Zhu S, et al.
JCI Insight
. 2023 May;
8(13).
PMID: 37219942
The incidence of early-onset colorectal cancer (EO-CRC) is rising and is poorly understood. Lifestyle factors and altered genetic background possibly contribute. Here, we performed targeted exon sequencing of archived leukocyte...
9.
Joshi S, Pandey R, Kumar A, Gupta V, Arya N
Cytokine
. 2023 Apr;
166:156155.
PMID: 37088002
Background: The tumor microenvironment plays a significant role in tumor growth, metastasis and chemoresistance via dysregulated signaling pathways. Toward this, an inflammatory chemokine, interleukin-8 (IL-8), is overexpressed in various cancers...
10.
Batai K, Chen Y, Rheinheimer B, Arora A, Pandey R, Heimark R, et al.
Cancer Med
. 2023 Apr;
12(11):12792-12801.
PMID: 37081700
Background: The United States is becoming increasingly diverse, but few molecular studies have assessed the progression of clear cell renal cell carcinoma (ccRCC) in diverse patient populations. This study examined...